Date(s) - Wednesday, October 24, 2018
12:00 pm - 1:30 pm
Flamingo Conference Resort and Spa
Buck Institute – The Age of Aging Research is Now
Dr. Eric Verdin
Eric Verdin, MD:
President and CEO
Eric Verdin is the President and Chief Executive Officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research. Dr. Verdin is also a Professor of Medicine at University of California, San Francisco.
Dr. Verdin’s laboratory focuses on the role of epigenetic regulators in the aging process. His laboratory was first to clone a family of enzymes, called HDACs, which regulate histone acetylation. Dr. Verdin studies how metabolism, diet and small molecules regulate the activity of HDACs and Sirtuins and thereby the aging process and its associated diseases, including Alzheimer’s. He has published more than 210 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1%) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations including the American Association for the Advancement of Science, the American Society for Clinical Investigation and the Association of American Physicians. He also serves on the Advisory Council of NIDA at the National Institutes of Health.
Dr. Verdin has extensive experience working with biotech companies. He is a founder of Acylin (purchased by Abbvie). He served on the scientific advisory boards of Elixir, Sirtris (purchased by GSK), of Calico (Google) and of Nokia, and also served as advisor to Sofinnova Ventures. Dr. Verdin has also worked for several years as consultant to Novartis, GSK, J&J, Altana, Roche and Pfizer and other biotech companies.
Current Research Projects
1. Role of reversible protein acetylation in aging. This work is focused on the role of key metabolites (NAD+ and acetylcoenzyme A) as sensors for the metabolic status of cells. These metabolites regulate the activity of epigenetic enzymes such as sirtuins and p300/CBP and thereby the activity of key gene programs involved in aging. The laboratory also focuses on the identification of inhibitors of p300 and activators of sirtuins as drugs that regulate the aging process and age-associated diseases.
2. Effect of β-hydroxybutyrate and ketogenic diet on aging and age-associated diseases (Alzheimer). The Verdin lab recently reported that β-hydroxybutyrate inhibits the activity of HDACs and thereby gene expression of key genes that regulate aging, including Foxo3a. The laboratory is currently exploring the effects of a ketogenic diet on lifespan in a mouse model of Alzheimer’s disease. They have also synthesized new β-hydroxybutyrate precursors and are testing them in models of aging.
3. Role of NAD+ metabolism in innate immune function. Chronic inflammation is a hallmark of aging. The Verdin lab studies how fluctuations in NAD+ metabolism regulate innate immune function. They are searching for small molecules that regulate key enzyme in NAD metabolism.
4. Study of accelerated aging in humans. The Verdin lab is currently studying models of accelerated human aging with a focus on patients infected with HIV and treated with antiretroviral therapy.
Verdin E. NAD⁺ in aging, metabolism, and neurodegeneration. Science. 2015 Dec 4; 350(6265):1208-13. doi: 10.1126/science.aac4854. Review. PubMed PMID: 26785480.
Verdin E, Ott M. 50 years of protein acetylation: from gene regulation to epigenetics, metabolism and beyond. Nat Rev Mol Cell Biol. 2015 Apr; 16(4):258-64. doi: 10.1038/nrm3931. PubMed PMID: 25549891.
Gut P, Verdin E. The nexus of chromatin regulation and intermediary metabolism. Nature. 2013 Oct 24; 502(7472):489-98. doi: 10.1038/nature12752. Review. PubMed PMID: 24153302.
Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E. Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science. 2013 Jan 11; 339(6116):211-4. doi: 10.1126/science.1227166. PubMed PMID: 23223453; PubMed Central PMCID: PMC3735349.
Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stančáková A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell. 2011 Oct 21; 44(2):177-90. doi: 10.1016/j.molcel.2011.07.019. PubMed PMID: 21856199; PubMed Central PMCID: PMC3563434.
Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, Grueter CA, Harris C, Biddinger S, Ilkayeva OR, Stevens RD, Li Y, Saha AK, Ruderman NB, Bain JR, Newgard CB, Farese RV Jr, Alt FW, Kahn CR, Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010 Mar 4; 464(7285):121-5. doi: 10.1038/nature08778. PubMed PMID: 20203611; PubMed Central PMCID: PMC2841477.